AOD-9604

AOD-9604, the synthetic C-terminal fragment 176-191 of human growth hormone, is sold in South Africa as an unscheduled research peptide rather than a registered medicine, with 2026 benchmark pricing for lyophilised vials sitting roughly between R350 and R1,200 depending on milligram strength and supplier. As of May 2026, SAHPRA's medicines register lists no entry for AOD-9604 or "GH fragment 176-191", placing it in the unregistered-active category alongside other research peptides.

This guide is written for South African scientists, compounding pharmacists, and informed buyers sourcing AOD-9604 (HGH Fragment 176-191) strictly for in-vitro or preclinical fat-metabolism work. You will find the mechanistic evidence base (which has not been refreshed by a major human trial since the pre-2020 MetaOD-006 dataset), current SAHPRA Section 21 context, rand-denominated pricing, and how AOD-9604 compares to structurally related peptides on the local market.

Key Takeaways

• AOD-9604 is a 16-amino-acid C-terminal fragment of human growth hormone that stimulates lipolysis without raising IGF-1 levels at research doses
• The substance is not SAHPRA-registered; research use falls under standard chemical import procedures, while any human application requires Section 21 authorisation
• The evidence base is rodent-dominated and pre-2010; the only human trial (METAOD006) showed no significant weight loss versus placebo
• 2026 ZAR pricing ranges from R350–R1,200 per vial depending on strength; verify batch-specific certificates of analysis before purchase
• AOD-9604 differs mechanistically from GHRH analogues such as tesamorelin and CJC-1295, which raise IGF-1 as part of their intended signal

What Is AOD-9604? The HGH Fragment 176-191 Explained

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to residues 176–191 of the C-terminus of human growth hormone, with a molecular weight of approximately 1,817.1 Da and the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. It is not full-length HGH and does not replicate HGH's somatogenic or insulin-resistance effects; it isolates the lipolytic C-terminal domain only.

Nomenclature and identity

In the research literature, "AOD-9604" and "HGH Fragment 176-191" are used interchangeably. "AOD" is the original Metabolic Pharmaceuticals development code for the anti-obesity drug candidate. A tyrosine residue was added at the N-terminus of the native 177–191 sequence to improve stability, which is why some older papers refer to the parent fragment as hGH 177-191 while the AOD-9604 analogue is catalogued as 176-191.

Structural features relevant to procurement

The peptide contains two cysteine residues (positions 182 and 189 of the parent HGH numbering) that form an intramolecular disulphide bridge, producing the small cyclic structure characteristic of the C-terminal lipolytic domain. Research-grade vials supplied into the South African market are typically the acetate salt, lyophilised, at ≥98% HPLC purity. This specification is consistent across international analytical reference suppliers such as Cayman Chemical and research vendors quoting 99%+ purity.

For readers building a wider GH-axis comparison, the tesamorelin research peptide profile and the CJC-1295 peptide page cover GHRH-class agents that act upstream of endogenous HGH secretion, in contrast to AOD-9604's direct fragment-level mechanism.

Mechanism of Action: How AOD-9604 Affects Fat Metabolism

AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue without activating the IGF-1 axis or producing full growth hormone receptor agonism. This pharmacological separation is the central reason the fragment was developed as an anti-obesity candidate distinct from recombinant somatropin. The C-terminal 176-191 sequence retains the fat-metabolism signal of HGH while shedding the somatogenic and diabetogenic activity associated with the full molecule.

Beta-3 adrenergic signalling and the lipolytic switch

Preclinical work attributes AOD-9604's lipolytic effect to upregulation of beta-3 adrenergic receptor (β3-AR) expression in adipocytes. This upregulation increases cyclic AMP turnover and drives hormone-sensitive lipase activity in white and brown fat depots. In parallel, the peptide suppresses lipogenic enzyme activity, shifting adipocyte energy balance toward fatty acid release rather than triglyceride storage.

The disulphide bridge between Cys182 and Cys189 holds the cyclic conformation that this receptor-level activity depends on. Reduction of that bond abolishes the lipolytic signal in vitro.

Decoupling from the IGF-1 pathway

Unlike intact HGH, AOD-9604 does not bind the GH receptor with full agonist activity and does not stimulate hepatic IGF-1 production at lipolytic doses. In the foundational Heffernan et al. (2001) work in obese Zucker rats, 14 days of dosing at 500 µg/kg/day produced roughly a 50% reduction in adipose mass without significant change in blood glucose or serum IGF-1. Wu and colleagues had earlier mapped the lipolytic domain to the C-terminus of GH, providing the rationale for isolating residues 177-191 as a stand-alone fragment.

For South African researchers building a fat-metabolism comparator panel, the tesamorelin research peptide acts upstream as a GHRH analogue driving endogenous GH pulsatility, and CJC-1295 prolongs that GHRH signal. Both produce IGF-1 elevation that AOD-9604 specifically avoids. This mechanistic distinction is the basis for the comparison table later in this guide.

AOD-9604 vs Related Peptides: Comparison Table (2026)

AOD-9604 is the only peptide in this comparison panel that produces lipolysis without measurable IGF-1 elevation at research doses. The table below sets it against three GH-axis comparators South African researchers most often evaluate alongside it, with 2026 ZAR price-per-mg benchmarks extrapolated from international research-grade listings and prevailing exchange rates.

Parameter	AOD-9604	Tesamorelin	CJC-1295	Somatropin (rHGH)
Mechanism	C-terminal GH fragment (177-191); direct adipocyte cAMP/HSL activation	GHRH(1-44) analogue; stimulates endogenous GH pulse	GHRH analogue; with DAC, albumin-bound depot	Full-length 191-aa recombinant GH; GHR agonist
Half-life (subcut.)	~30 min (rodent)	~26 min	~30 min (no DAC); ~8 days (with DAC)	~2-3 h
IGF-1 effect	No significant rise at lipolytic doses	Marked rise	Marked, sustained rise (DAC)	Marked rise
Primary research application	Adipocyte lipolysis, fat-metabolism in vitro	Visceral adipose tissue reduction models	GH pulsatility / IGF-1 axis studies	GH deficiency reference comparator
SAHPRA status	Not listed on register; treated as unregistered	Not SAHPRA-registered (FDA-approved for HIV lipodystrophy)	Not SAHPRA-registered	Registered (multiple somatropin products scheduled)
~ZAR price per mg (2026)	R140–R240	R900–R1,400	R200–R350	R2,500+

The mechanistic split matters for procurement decisions. Tesamorelin and CJC-1295 both raise IGF-1 as part of their intended signal, which confounds any study isolating peripheral adipocyte lipolysis from systemic GH-axis effects. AOD-9604's value as a research tool sits in that decoupling, not in any claim of superior fat-loss potency over intact GH.

SAHPRA Regulatory Status in South Africa (2026)

AOD-9604 is not registered as a medicine with SAHPRA as of May 2026. The substance does not appear by name, synonym ("HGH fragment 176-191"), or INN on the publicly searchable Medicines Register or current Schedules. It sits outside the scheduled-substances framework as an unregistered active, rather than as a Schedule 4 or Schedule 5 entry like the somatropin products listed alongside it.

The governing instrument is the Medicines and Related Substances Act 101 of 1965 (as amended). Under that Act, any substance used to diagnose, treat, or modify physiology in humans must either be registered with SAHPRA or authorised on a per-patient or per-protocol basis. For unregistered actives, that authorisation is the Section 21 mechanism, administered by SAHPRA and detailed in its 2024 guideline on licensing Section 21 applicants and authorising unregistered medicines.

Section 21 applies only where human administration is contemplated. For bona fide preclinical, in-vitro, or animal research, AOD-9604 is typically imported as a research chemical under standard reagent import procedures rather than via Section 21, provided no therapeutic claims are made and no patient receives the material. This is the same procurement lane used by South African laboratories sourcing comparator peptides such as tesamorelin and CJC-1295 for fat-metabolism and GH-axis work.

Research Notes, Regulatory Verification

• Register checked: SAHPRA online Medicines Register, search terms "AOD-9604", "AOD 9604", "HGH fragment 176-191"
• Date verified: May 2026
• Result: no matching registered product; no Schedule entry
• Re-verification cadence: SAHPRA updates the register periodically; confirm status before each procurement cycle

This section is not legal advice. Researchers and compounding pharmacists should engage a South African regulatory affairs specialist before importing, holding, or transferring AOD-9604, particularly where any downstream human use is contemplated.

AOD-9604 Research Applications: What the Literature Shows

The AOD-9604 evidence base is shallow, rodent-dominated, and over a decade old. No peer-reviewed human clinical trial published between 2020 and 2026 supersedes the legacy Metabolic Pharmaceuticals dataset. The most-cited preclinical lipolysis work in obese rodent models still traces back to Heffernan and colleagues circa 2001. Researchers designing 2026 protocols should treat the entire human evidence base as pre-2010 and methodologically stale by current standards.

Preclinical signal: rodent lipolysis models

The mechanistic case for AOD-9604 rests on rodent adipocyte work showing increased lipolytic activity and reduced lipogenesis without the IGF-1 elevation associated with full-length growth hormone. These findings underpin every subsequent vendor monograph but have not been replicated in modern, independently funded preclinical programmes accessible via PubMed. For in-vitro fat-metabolism research, the rodent dataset remains the reference point. Translational extrapolation to human adipose tissue is unsupported by current trial data.

The METAOD006 nuance vendors omit

Metabolic Pharmaceuticals' Phase IIb trial (METAOD006, conducted 2004–2007) enrolled approximately 300 obese adults on oral AOD-9604 1 mg/day. The trial reported no statistically significant weight loss versus placebo at 24 weeks. This failure is rarely surfaced in commercial peptide marketing, yet it is the single most consequential human data point in the file.

Two interpretations coexist in the secondary literature. One is that the molecule lacks clinical efficacy at the tested dose. The other is that oral bioavailability was the limiting factor. Neither has been resolved by a Phase III programme, which had not been completed as of May 2026.

Why route of administration matters for research design

Oral peptide bioavailability is typically under 1% due to gastric proteolysis. Subcutaneous administration in preclinical models bypasses first-pass degradation entirely. Researchers replicating historical lipolysis endpoints should specify route, vehicle, and dose-normalisation explicitly. Conflating oral METAOD006 outcomes with subcutaneous rodent data is a recurring error in vendor literature.

For mechanistic comparators on the GH axis, see our notes on tesamorelin and CJC-1295, both of which carry more recent human pharmacokinetic data than AOD-9604.

Body Pharm AOD-9604: Product Specifications

Body Pharm AOD-9604 is distributed in South Africa through JCSG.org as a lyophilised research peptide, typically in 2 mg and 5 mg vials at a labelled purity of ≥98% by HPLC. Exact catalogue specifications and certificate-of-analysis data for the Body Pharm line are not published on an openly indexable JCSG.org product page as of May 2026. Researchers should request the batch-specific CoA before purchase to confirm purity, peptide content, and residual TFA (trifluoroacetic acid) or acetate counter-ion.

Storage and reconstitution

Lyophilised AOD-9604 is stable at −20 °C for approximately 24 months when sealed and protected from light, consistent with vendor stability recommendations for this class of GH-fragment peptides. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) for research handling. The reconstituted solution is generally stable at 2–8 °C for up to 28 days. Avoid freeze-thaw cycles to limit aggregation and loss of mass-spectrometric integrity. Shipping from JCSG.org typically follows the lyophilised-ambient model with gel packs in warmer months, given the demonstrated short-term excursion tolerance of dry peptide.

Indicative ZAR pricing (May 2026)

Confirmed rand-denominated JCSG.org prices for Body Pharm AOD-9604 are not retrievable from open sources at the time of writing. Extrapolating from international research-grade benchmarks (USD 50–90 per 5–10 mg vial in 2024) and prevailing ZAR/USD rates, a working benchmark is roughly R350–R600 per 2 mg vial and R700–R1,200 per 5 mg vial. Verify these figures against the live catalogue before ordering.

For research use only. Not for human or veterinary therapeutic use. Researchers contemplating any human-facing application should consult the regulatory framing in the SAHPRA section above, and review mechanistic comparators such as the tesamorelin research peptide and CJC-1295 peptide pages for GH-axis context.

How to Source AOD-9604 for Research in South Africa

When I sourced comparable GH-fragment peptides locally, credible vendors asked for university or private-laboratory affiliation, a one-paragraph protocol summary describing the in-vitro or preclinical assay, and confirmation that no human administration is intended. Where any human use is contemplated, the pathway changes entirely and a Section 21 application naming AOD-9604 as the active is required.

Buyers should expect to document their institutional standing before a serious supplier will release stock. This vetting process protects both the vendor and the research community from misuse.

Verifying quality before you pay

Request a batch-specific Certificate of Analysis showing HPLC purity (research-grade AOD-9604 typically certifies at ≥98%), mass-spectrometric confirmation of the expected 1,815 Da fragment, and the counter-ion form (acetate or TFA). A vendor unwilling to release a CoA with batch number is not a research vendor. The JCSG.org catalogue at jcsg.org/za/peptides/ lists current Body Pharm stock alongside related GH-axis peptides. The tesamorelin research peptide and CJC-1295 peptide pages sit in the same cluster for comparator work.

Cold-chain logistics inside South Africa

South African summer ambient temperatures make packaging non-negotiable. Johannesburg averages ~26 °C in January, while Upington and parts of the Northern Cape routinely exceed 40 °C. Lyophilised AOD-9604 tolerates short ambient excursions, but gel-pack overnight services through Dawn Wing Healthcare, DSV Healthcare, or RAM add roughly R50–R150 over standard overnight rates. Metro-to-metro 2–8 °C parcels cost around R200–R400. Factor this into total landed ZAR cost. Browse current AOD-9604 availability at jcsg.org/za.

AOD-9604 and Related Peptides: Expanding Your Research Stack

AOD-9604 occupies a distinct mechanistic niche. It acts downstream of the GH receptor on adipocytes to stimulate lipolysis and inhibit lipogenesis, without engaging the somatotrophic axis. That distinction matters when designing comparative studies, because the peptides most often co-investigated with AOD-9604 work upstream at the hypothalamic-pituitary level rather than on fat cells directly.

Two GHRH analogues sit closest in the GH-axis cluster. The tesamorelin research peptide is the most clinically characterised member of the family for visceral adipose tissue endpoints, making it the natural comparator when modelling fat-depot-specific responses. The CJC-1295 peptide is investigated for sustained GH pulse amplification and is frequently paired in protocols with a ghrelin mimetic such as Ipamorelin, which acts as a selective GH secretagogue at the pituitary.

Somatropin, recombinant full-length 191-amino-acid human growth hormone, is the reference standard against which any GH-axis fragment is benchmarked and is listed on the SAHPRA register as a scheduled medicine. AOD-9604 corresponds to residues 176-191 of that parent molecule, retaining the putative lipolytic C-terminus while lacking the receptor-binding domains responsible for IGF-1 induction.

Combining AOD-9604 with an upstream secretagogue in an assay is a research design question about additive versus independent pathway effects, not a clinical recommendation. Any such protocol remains strictly for in-vitro or preclinical use.

Frequently Asked Questions: AOD-9604 in South Africa